JP2023519666A - Gpr52モジュレーター化合物 - Google Patents
Gpr52モジュレーター化合物 Download PDFInfo
- Publication number
- JP2023519666A JP2023519666A JP2022555137A JP2022555137A JP2023519666A JP 2023519666 A JP2023519666 A JP 2023519666A JP 2022555137 A JP2022555137 A JP 2022555137A JP 2022555137 A JP2022555137 A JP 2022555137A JP 2023519666 A JP2023519666 A JP 2023519666A
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- trifluoromethyl
- pyridin
- benzyl
- pyrazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 137
- 102100033046 G-protein coupled receptor 52 Human genes 0.000 title claims abstract description 40
- 101000871149 Homo sapiens G-protein coupled receptor 52 Proteins 0.000 title claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 208000035475 disorder Diseases 0.000 claims abstract description 25
- 125000001153 fluoro group Chemical group F* 0.000 claims description 86
- 125000000217 alkyl group Chemical group 0.000 claims description 80
- 125000005843 halogen group Chemical group 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 125000003545 alkoxy group Chemical group 0.000 claims description 28
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 26
- 125000004429 atom Chemical group 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 15
- 208000028017 Psychotic disease Diseases 0.000 claims description 15
- 208000019901 Anxiety disease Diseases 0.000 claims description 12
- 208000012661 Dyskinesia Diseases 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 208000029560 autism spectrum disease Diseases 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 230000033001 locomotion Effects 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 10
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 9
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 9
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 9
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 9
- 208000019906 panic disease Diseases 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 208000027626 Neurocognitive disease Diseases 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 208000030990 Impulse-control disease Diseases 0.000 claims description 7
- 208000010877 cognitive disease Diseases 0.000 claims description 7
- 208000007415 Anhedonia Diseases 0.000 claims description 6
- 208000009017 Athetosis Diseases 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
- 208000030336 Bipolar and Related disease Diseases 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 125000006519 CCH3 Chemical group 0.000 claims description 6
- 206010008748 Chorea Diseases 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000012601 choreatic disease Diseases 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 208000031424 hyperprolactinemia Diseases 0.000 claims description 6
- 210000001577 neostriatum Anatomy 0.000 claims description 6
- 208000020016 psychiatric disease Diseases 0.000 claims description 6
- 208000037857 Alzheimer's disease agitation Diseases 0.000 claims description 5
- 206010012218 Delirium Diseases 0.000 claims description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 5
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 5
- 201000002832 Lewy body dementia Diseases 0.000 claims description 5
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 5
- 208000016620 Tourette disease Diseases 0.000 claims description 5
- 201000004810 Vascular dementia Diseases 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- PRTJKFMGXBDQAG-UHFFFAOYSA-N ClC1=NN(C=C1C(=O)N)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F Chemical compound ClC1=NN(C=C1C(=O)N)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F PRTJKFMGXBDQAG-UHFFFAOYSA-N 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- WEMUBGUHPFYKBA-UHFFFAOYSA-N FC=1C=C(C=C(C=1)C(F)(F)F)C(C1=NC=CC(=C1)N1N=C(C(=C1)C(=O)N)C)O Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C(C1=NC=CC(=C1)N1N=C(C(=C1)C(=O)N)C)O WEMUBGUHPFYKBA-UHFFFAOYSA-N 0.000 claims description 4
- GPRAUIRJQYAATD-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2C)C(=O)N)CO)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2C)C(=O)N)CO)C=C(C=1)C(F)(F)F GPRAUIRJQYAATD-UHFFFAOYSA-N 0.000 claims description 4
- TVWSOAIVRVCEPG-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2CO)C(=O)N)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2CO)C(=O)N)C)C=C(C=1)C(F)(F)F TVWSOAIVRVCEPG-UHFFFAOYSA-N 0.000 claims description 4
- RGAYVCZFQZVMHX-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2CO)C(=O)NCCO)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2CO)C(=O)NCCO)C)C=C(C=1)C(F)(F)F RGAYVCZFQZVMHX-UHFFFAOYSA-N 0.000 claims description 4
- MZMCSAUVMPYSSV-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2)C(=O)N)C=C(C=1)C(F)(F)F MZMCSAUVMPYSSV-UHFFFAOYSA-N 0.000 claims description 4
- ILOYSDVMJADIFC-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2)C(=O)NC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2)C(=O)NC)C=C(C=1)C(F)(F)F ILOYSDVMJADIFC-UHFFFAOYSA-N 0.000 claims description 4
- QHTLJWWBRWZGMU-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2C)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2C)C(=O)N)C=C(C=1)C(F)(F)F QHTLJWWBRWZGMU-UHFFFAOYSA-N 0.000 claims description 4
- JVWDSCHCNLHECT-UHFFFAOYSA-N FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)C(=O)N)CO)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)C(=O)N)CO)C=C(C=1)C(F)(F)F JVWDSCHCNLHECT-UHFFFAOYSA-N 0.000 claims description 4
- FYSUPCHUZRYBLC-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=N2)C(=O)N)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=N2)C(=O)N)C)C=C(C=1)C(F)(F)F FYSUPCHUZRYBLC-UHFFFAOYSA-N 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000018300 basal ganglia disease Diseases 0.000 claims description 4
- 230000003542 behavioural effect Effects 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 208000008811 Agoraphobia Diseases 0.000 claims description 3
- 206010001540 Akathisia Diseases 0.000 claims description 3
- 208000000044 Amnesia Diseases 0.000 claims description 3
- 208000031091 Amnestic disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 206010011168 Cortical dysfunction Diseases 0.000 claims description 3
- 206010012239 Delusion Diseases 0.000 claims description 3
- 208000024254 Delusional disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000019246 Developmental coordination disease Diseases 0.000 claims description 3
- VJQQUSIPOIWCAA-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C(=O)N)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C(=O)N)OC)C=C(C=1)C(F)(F)F VJQQUSIPOIWCAA-UHFFFAOYSA-N 0.000 claims description 3
- SUELXBRVYAJSLN-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2C)C(=O)N)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2C)C(=O)N)C)C=C(C=1)C(F)(F)F SUELXBRVYAJSLN-UHFFFAOYSA-N 0.000 claims description 3
- XPLJRXTVLLQJMS-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N)OC)C=C(C=1)C(F)(F)F XPLJRXTVLLQJMS-UHFFFAOYSA-N 0.000 claims description 3
- KYFBMRRVXSFGAB-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N2CCCC2)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N2CCCC2)C)C=C(C=1)C(F)(F)F KYFBMRRVXSFGAB-UHFFFAOYSA-N 0.000 claims description 3
- GFITZLUTWDBNOK-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)NCCO)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)NCCO)C)C=C(C=1)C(F)(F)F GFITZLUTWDBNOK-UHFFFAOYSA-N 0.000 claims description 3
- 208000004547 Hallucinations Diseases 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 208000028482 Hypothalamic disease Diseases 0.000 claims description 3
- 208000025282 Hypothalamo-pituitary disease Diseases 0.000 claims description 3
- 208000019896 Motor Skills disease Diseases 0.000 claims description 3
- 206010028403 Mutism Diseases 0.000 claims description 3
- 208000002033 Myoclonus Diseases 0.000 claims description 3
- 206010034912 Phobia Diseases 0.000 claims description 3
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 3
- 208000014993 Pituitary disease Diseases 0.000 claims description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 3
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims description 3
- 206010036832 Prolactinoma Diseases 0.000 claims description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 3
- 208000020186 Schizophreniform disease Diseases 0.000 claims description 3
- 206010039917 Selective mutism Diseases 0.000 claims description 3
- 206010041250 Social phobia Diseases 0.000 claims description 3
- 208000005392 Spasm Diseases 0.000 claims description 3
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 3
- 206010044565 Tremor Diseases 0.000 claims description 3
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000006986 amnesia Effects 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 208000028683 bipolar I disease Diseases 0.000 claims description 3
- 208000022257 bipolar II disease Diseases 0.000 claims description 3
- 208000026725 cyclothymic disease Diseases 0.000 claims description 3
- 231100000868 delusion Toxicity 0.000 claims description 3
- 201000010064 diabetes insipidus Diseases 0.000 claims description 3
- 201000002545 drug psychosis Diseases 0.000 claims description 3
- 230000002996 emotional effect Effects 0.000 claims description 3
- 208000024714 major depressive disease Diseases 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 230000008450 motivation Effects 0.000 claims description 3
- 239000003176 neuroleptic agent Substances 0.000 claims description 3
- 230000000701 neuroleptic effect Effects 0.000 claims description 3
- 208000026529 non-functioning endocrine neoplasm Diseases 0.000 claims description 3
- 125000003566 oxetanyl group Chemical group 0.000 claims description 3
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 3
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 claims description 3
- 208000022610 schizoaffective disease Diseases 0.000 claims description 3
- 201000001716 specific phobia Diseases 0.000 claims description 3
- ZXXKIMGZXCNUPR-UHFFFAOYSA-N C(#N)C1=NN(C=C1C(=O)N)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F Chemical compound C(#N)C1=NN(C=C1C(=O)N)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F ZXXKIMGZXCNUPR-UHFFFAOYSA-N 0.000 claims description 2
- GYANPUHJWCCUHQ-UHFFFAOYSA-N C(C)C1=NN(C=C1C(=O)N)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F Chemical compound C(C)C1=NN(C=C1C(=O)N)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F GYANPUHJWCCUHQ-UHFFFAOYSA-N 0.000 claims description 2
- CKSNEXSYQICAGK-UHFFFAOYSA-N C1(CC1)C1=NN(C=C1C(=O)N)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F Chemical compound C1(CC1)C1=NN(C=C1C(=O)N)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F CKSNEXSYQICAGK-UHFFFAOYSA-N 0.000 claims description 2
- AJXURYJXIQSVEY-UHFFFAOYSA-N CC(C(C(NCCO)=O)=C1CO)=NN1C1=CC(CC2=CC(F)=CC(C(F)(F)F)=C2)=NC=C1 Chemical compound CC(C(C(NCCO)=O)=C1CO)=NN1C1=CC(CC2=CC(F)=CC(C(F)(F)F)=C2)=NC=C1 AJXURYJXIQSVEY-UHFFFAOYSA-N 0.000 claims description 2
- OOPKIZJHSUKFGE-UHFFFAOYSA-N FC(C1=NN(C=C1C(=O)N)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F)F Chemical compound FC(C1=NN(C=C1C(=O)N)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F)F OOPKIZJHSUKFGE-UHFFFAOYSA-N 0.000 claims description 2
- JTUZHKQOPXXINW-UHFFFAOYSA-N FC(C=1C=C(C=C(C=1)F)CC1=CC(=NC=C1)N1N=C(C(=C1)C(=O)NC)C)F Chemical compound FC(C=1C=C(C=C(C=1)F)CC1=CC(=NC=C1)N1N=C(C(=C1)C(=O)NC)C)F JTUZHKQOPXXINW-UHFFFAOYSA-N 0.000 claims description 2
- BFJBJRPRBTVAFH-UHFFFAOYSA-N FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C(=O)N)C)C=C(C=1)F)F Chemical compound FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C(=O)N)C)C=C(C=1)F)F BFJBJRPRBTVAFH-UHFFFAOYSA-N 0.000 claims description 2
- ILPMKYQSFUWOKJ-UHFFFAOYSA-N FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2CO)C(=O)N)C)C=C(C=1)F)F Chemical compound FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2CO)C(=O)N)C)C=C(C=1)F)F ILPMKYQSFUWOKJ-UHFFFAOYSA-N 0.000 claims description 2
- GXACJDXASGTCBV-UHFFFAOYSA-N FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)N)C=C(C=1)F)F Chemical compound FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)N)C=C(C=1)F)F GXACJDXASGTCBV-UHFFFAOYSA-N 0.000 claims description 2
- CTSDHSHJCRSCJO-UHFFFAOYSA-N FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)NC)C=C(C=1)F)F Chemical compound FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)NC)C=C(C=1)F)F CTSDHSHJCRSCJO-UHFFFAOYSA-N 0.000 claims description 2
- INQWQEXVYJDUNR-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C(=O)N)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C(=O)N)C)C=C(C=1)C(F)(F)F INQWQEXVYJDUNR-UHFFFAOYSA-N 0.000 claims description 2
- XVMTTWHUZDNDRK-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C)C(=O)N)C=C(C=1)C(F)(F)F XVMTTWHUZDNDRK-UHFFFAOYSA-N 0.000 claims description 2
- DMAVXHPGNSBBKX-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C)C(=O)NC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C)C(=O)NC)C=C(C=1)C(F)(F)F DMAVXHPGNSBBKX-UHFFFAOYSA-N 0.000 claims description 2
- MDHRJCXRXHMSJD-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)CO)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)CO)C(=O)N)C=C(C=1)C(F)(F)F MDHRJCXRXHMSJD-UHFFFAOYSA-N 0.000 claims description 2
- BSMFHECGRIFHBR-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)CO)C(=O)NC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)CO)C(=O)NC)C=C(C=1)C(F)(F)F BSMFHECGRIFHBR-UHFFFAOYSA-N 0.000 claims description 2
- DUGFYAZDZBAAGC-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2CO)C(=O)NC)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2CO)C(=O)NC)C)C=C(C=1)C(F)(F)F DUGFYAZDZBAAGC-UHFFFAOYSA-N 0.000 claims description 2
- VUXUWDBAAYYXNK-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=N2)C(=O)N)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=N2)C(=O)N)C)C=C(C=1)C(F)(F)F VUXUWDBAAYYXNK-UHFFFAOYSA-N 0.000 claims description 2
- ATZFBBFRACFFGB-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=N2)C(=O)NC)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=N2)C(=O)NC)C)C=C(C=1)C(F)(F)F ATZFBBFRACFFGB-UHFFFAOYSA-N 0.000 claims description 2
- XUQUTQSVYYSUCF-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)N(C)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)N(C)C)C=C(C=1)C(F)(F)F XUQUTQSVYYSUCF-UHFFFAOYSA-N 0.000 claims description 2
- YGQBLUSKTOARGQ-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)N)C=C(C=1)C(F)(F)F YGQBLUSKTOARGQ-UHFFFAOYSA-N 0.000 claims description 2
- BKAPUEBEBJNMRI-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)N2CCCC2)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)N2CCCC2)C=C(C=1)C(F)(F)F BKAPUEBEBJNMRI-UHFFFAOYSA-N 0.000 claims description 2
- QWBWJHGJOOFQHD-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)NC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)NC)C=C(C=1)C(F)(F)F QWBWJHGJOOFQHD-UHFFFAOYSA-N 0.000 claims description 2
- GGFSDKKJWUBMIF-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)NC2COC2)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)NC2COC2)C=C(C=1)C(F)(F)F GGFSDKKJWUBMIF-UHFFFAOYSA-N 0.000 claims description 2
- RGQNBDOZWDMZPI-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)NCCO)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)NCCO)C=C(C=1)C(F)(F)F RGQNBDOZWDMZPI-UHFFFAOYSA-N 0.000 claims description 2
- KGJROHAOTOUDOW-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)NCCOC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)NCCOC)C=C(C=1)C(F)(F)F KGJROHAOTOUDOW-UHFFFAOYSA-N 0.000 claims description 2
- PCMBGHRXIKEBBP-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C)C(=O)N)C=C(C=1)C(F)(F)F PCMBGHRXIKEBBP-UHFFFAOYSA-N 0.000 claims description 2
- NDBKEQSUIQYMQD-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C)C(=O)NC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C)C(=O)NC)C=C(C=1)C(F)(F)F NDBKEQSUIQYMQD-UHFFFAOYSA-N 0.000 claims description 2
- SQOMWVIFUCFOSG-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2CO)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2CO)C(=O)N)C=C(C=1)C(F)(F)F SQOMWVIFUCFOSG-UHFFFAOYSA-N 0.000 claims description 2
- XNJXYPPAHWWLKF-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=N2)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=N2)C(=O)N)C=C(C=1)C(F)(F)F XNJXYPPAHWWLKF-UHFFFAOYSA-N 0.000 claims description 2
- AZOPMPJYAAQLNW-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=N2)C(=O)NC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=N2)C(=O)NC)C=C(C=1)C(F)(F)F AZOPMPJYAAQLNW-UHFFFAOYSA-N 0.000 claims description 2
- QCSOLJHMXXAWFA-UHFFFAOYSA-N FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)C(=O)NC)CO)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)C(=O)NC)CO)C=C(C=1)C(F)(F)F QCSOLJHMXXAWFA-UHFFFAOYSA-N 0.000 claims description 2
- UJWSGUYCEMWBDH-UHFFFAOYSA-N FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)C)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)C)C(=O)N)C=C(C=1)C(F)(F)F UJWSGUYCEMWBDH-UHFFFAOYSA-N 0.000 claims description 2
- PUKVTEBGGGOZAM-UHFFFAOYSA-N FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)CO)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)CO)C(=O)N)C=C(C=1)C(F)(F)F PUKVTEBGGGOZAM-UHFFFAOYSA-N 0.000 claims description 2
- SXUDXFDDDYUMBA-UHFFFAOYSA-N FC=1C=C(CC2=NC=C(C(=C2)N2N=C(C(=C2)C(=O)N)C)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=C(C(=C2)N2N=C(C(=C2)C(=O)N)C)C)C=C(C=1)C(F)(F)F SXUDXFDDDYUMBA-UHFFFAOYSA-N 0.000 claims description 2
- KBENBCBIXIVCEJ-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N(C)C)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N(C)C)C)C=C(C=1)C(F)(F)F KBENBCBIXIVCEJ-UHFFFAOYSA-N 0.000 claims description 2
- BJEDYZKYTGLZQX-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N)C(F)(F)F)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N)C(F)(F)F)C=C(C=1)C(F)(F)F BJEDYZKYTGLZQX-UHFFFAOYSA-N 0.000 claims description 2
- TZFCYVQLAAJFEI-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N)C)C=C(C=1)C(F)(F)F TZFCYVQLAAJFEI-UHFFFAOYSA-N 0.000 claims description 2
- IZPLWZLDFXJNAK-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)NC)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)NC)C)C=C(C=1)C(F)(F)F IZPLWZLDFXJNAK-UHFFFAOYSA-N 0.000 claims description 2
- DZNNDOVPIAMCSE-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)NC2COC2)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)NC2COC2)C)C=C(C=1)C(F)(F)F DZNNDOVPIAMCSE-UHFFFAOYSA-N 0.000 claims description 2
- DOCVVZWPUJEIRL-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)NCCOC)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)NCCOC)C)C=C(C=1)C(F)(F)F DOCVVZWPUJEIRL-UHFFFAOYSA-N 0.000 claims description 2
- IGLKYKXZSFRGNO-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2CO)C(=O)N)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2CO)C(=O)N)C)C=C(C=1)C(F)(F)F IGLKYKXZSFRGNO-UHFFFAOYSA-N 0.000 claims description 2
- AWBITKOXWLKYTN-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C=C2)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C=C2)C(=O)N)C=C(C=1)C(F)(F)F AWBITKOXWLKYTN-UHFFFAOYSA-N 0.000 claims description 2
- DCIDIXFLWZCVFE-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C=C2)C(=O)NC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C=C2)C(=O)NC)C=C(C=1)C(F)(F)F DCIDIXFLWZCVFE-UHFFFAOYSA-N 0.000 claims description 2
- LIWYXCDJEGOSBA-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=CC(=C2)C(=O)N)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=CC(=C2)C(=O)N)C=C(C=1)C(F)(F)F LIWYXCDJEGOSBA-UHFFFAOYSA-N 0.000 claims description 2
- 208000000810 Separation Anxiety Diseases 0.000 claims description 2
- 206010042008 Stereotypy Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 210000003591 cerebellar nuclei Anatomy 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 210000001652 frontal lobe Anatomy 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940075993 receptor modulator Drugs 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 167
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 120
- 239000002904 solvent Substances 0.000 description 119
- 239000011541 reaction mixture Substances 0.000 description 102
- 238000000034 method Methods 0.000 description 97
- 239000000543 intermediate Substances 0.000 description 92
- 235000019439 ethyl acetate Nutrition 0.000 description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 82
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 71
- 239000012044 organic layer Substances 0.000 description 64
- 239000007787 solid Substances 0.000 description 58
- 239000000243 solution Substances 0.000 description 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 39
- 101710108870 G-protein coupled receptor 52 Proteins 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 239000007832 Na2SO4 Substances 0.000 description 33
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 33
- 238000003818 flash chromatography Methods 0.000 description 33
- 239000010410 layer Substances 0.000 description 33
- 229910052938 sodium sulfate Inorganic materials 0.000 description 33
- 235000011152 sodium sulphate Nutrition 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- 235000002639 sodium chloride Nutrition 0.000 description 29
- 239000012267 brine Substances 0.000 description 27
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- -1 CN Chemical group 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000000746 purification Methods 0.000 description 13
- 239000003643 water by type Substances 0.000 description 13
- PVQLHROIURJTIG-UHFFFAOYSA-N FC1=NC=CC(=C1)CC1=CC(=CC(=C1)C(F)(F)F)F Chemical compound FC1=NC=CC(=C1)CC1=CC(=CC(=C1)C(F)(F)F)F PVQLHROIURJTIG-UHFFFAOYSA-N 0.000 description 12
- 238000000825 ultraviolet detection Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 239000000556 agonist Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 239000007821 HATU Substances 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- XVGWDIQXGWVTIG-UHFFFAOYSA-N FC1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F Chemical compound FC1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F XVGWDIQXGWVTIG-UHFFFAOYSA-N 0.000 description 8
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 8
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 229960001948 caffeine Drugs 0.000 description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 101150003085 Pdcl gene Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- PAQZWJGSJMLPMG-UHFFFAOYSA-N propylphosphonic anhydride Substances CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
- 238000013222 sprague-dawley male rat Methods 0.000 description 5
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 5
- LCVWAXYGYMZJER-UHFFFAOYSA-N 1-(bromomethyl)-3-fluoro-5-(trifluoromethyl)benzene Chemical compound FC1=CC(CBr)=CC(C(F)(F)F)=C1 LCVWAXYGYMZJER-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- DDHHQUWWQHXUSA-UHFFFAOYSA-N ClCC1=CC(=CC(=C1)F)C(F)F Chemical compound ClCC1=CC(=CC(=C1)F)C(F)F DDHHQUWWQHXUSA-UHFFFAOYSA-N 0.000 description 4
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 4
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- DLCRRDMHCZRVPB-UHFFFAOYSA-N ethyl 2-methyl-4-oxofuran-3-carboxylate Chemical compound CCOC(=O)C1=C(C)OCC1=O DLCRRDMHCZRVPB-UHFFFAOYSA-N 0.000 description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 4
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- AOSIKKGXQJIQFA-UHFFFAOYSA-N FC1=NC(=CC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F Chemical compound FC1=NC(=CC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F AOSIKKGXQJIQFA-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000035863 hyperlocomotion Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- ORUCTBNNYKZMSK-UHFFFAOYSA-N methyl 1h-pyrazole-5-carboxylate Chemical compound COC(=O)C=1C=CNN=1 ORUCTBNNYKZMSK-UHFFFAOYSA-N 0.000 description 3
- MSWADDMTXJEOCH-UHFFFAOYSA-N methyl 2-acetyl-4-methoxy-3-oxobutanoate Chemical compound COCC(=O)C(C(C)=O)C(=O)OC MSWADDMTXJEOCH-UHFFFAOYSA-N 0.000 description 3
- 230000009461 neurocognitive dysfunction Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 2
- ZVXKYWHJBYIYNI-UHFFFAOYSA-N 1h-pyrazole-4-carboxamide Chemical compound NC(=O)C=1C=NNC=1 ZVXKYWHJBYIYNI-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- PTPTZLXZHPPVKG-UHFFFAOYSA-N 4-bromo-2-fluoropyridine Chemical compound FC1=CC(Br)=CC=N1 PTPTZLXZHPPVKG-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- POBWFPHAPLKUCP-UHFFFAOYSA-N ClC1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F Chemical compound ClC1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F POBWFPHAPLKUCP-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- CWNWKZHDQAOLAR-UHFFFAOYSA-N FC(C=1C=C(C(=O)OC)C=C(C=1)F)F Chemical compound FC(C=1C=C(C(=O)OC)C=C(C=1)F)F CWNWKZHDQAOLAR-UHFFFAOYSA-N 0.000 description 2
- MYAPPCIRFSELTH-UHFFFAOYSA-N FC(C=1C=C(C=C(C=1)F)CO)F Chemical compound FC(C=1C=C(C=C(C=1)F)CO)F MYAPPCIRFSELTH-UHFFFAOYSA-N 0.000 description 2
- HRJDASCMUXKOPB-UHFFFAOYSA-N FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C(=O)O)C)C=C(C=1)F)F Chemical compound FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C(=O)O)C)C=C(C=1)F)F HRJDASCMUXKOPB-UHFFFAOYSA-N 0.000 description 2
- OVJNCMLVEAVFCB-UHFFFAOYSA-N FC(C=1C=C(CC2=CC(=NC=C2)NN)C=C(C=1)F)F Chemical compound FC(C=1C=C(CC2=CC(=NC=C2)NN)C=C(C=1)F)F OVJNCMLVEAVFCB-UHFFFAOYSA-N 0.000 description 2
- IVJVBAUNDAFUSN-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C(=O)OCC)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C(=O)OCC)OC)C=C(C=1)C(F)(F)F IVJVBAUNDAFUSN-UHFFFAOYSA-N 0.000 description 2
- VQBWOVRPWGUCHW-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)CO)C(=O)O)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)CO)C(=O)O)C=C(C=1)C(F)(F)F VQBWOVRPWGUCHW-UHFFFAOYSA-N 0.000 description 2
- QENRJBDMEZWCGH-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2C)C(=O)O)CO)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2C)C(=O)O)CO)C=C(C=1)C(F)(F)F QENRJBDMEZWCGH-UHFFFAOYSA-N 0.000 description 2
- ZJBBNRWXNLZKEU-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C(=O)OC)C(=O)O)C=C(C=1)C(F)(F)F Chemical class FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C(=O)OC)C(=O)O)C=C(C=1)C(F)(F)F ZJBBNRWXNLZKEU-UHFFFAOYSA-N 0.000 description 2
- LBXHIOLVYSIHDF-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2)C(=O)O)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2)C(=O)O)C=C(C=1)C(F)(F)F LBXHIOLVYSIHDF-UHFFFAOYSA-N 0.000 description 2
- SKSMWQWWGUPENX-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)NN)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)NN)C=C(C=1)C(F)(F)F SKSMWQWWGUPENX-UHFFFAOYSA-N 0.000 description 2
- AORXWKYJVFWNKO-UHFFFAOYSA-N FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)C(=O)O)C(=O)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)C(=O)O)C(=O)OC)C=C(C=1)C(F)(F)F AORXWKYJVFWNKO-UHFFFAOYSA-N 0.000 description 2
- NJXRCUIKJMVXND-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=N2)C(=O)OC)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=N2)C(=O)OC)C)C=C(C=1)C(F)(F)F NJXRCUIKJMVXND-UHFFFAOYSA-N 0.000 description 2
- DOKSSXRVXBTDAD-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)NN)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)NN)C=C(C=1)C(F)(F)F DOKSSXRVXBTDAD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229910002666 PdCl2 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 206010007776 catatonia Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- RPFZLULJSPXVDO-FNORWQNLSA-N methyl (2e)-2-(dimethylaminomethylidene)-3-oxobutanoate Chemical compound COC(=O)C(\C(C)=O)=C\N(C)C RPFZLULJSPXVDO-FNORWQNLSA-N 0.000 description 2
- VFTZKSMAJVLWOV-UHFFFAOYSA-N methyl 1h-pyrazole-4-carboxylate Chemical compound COC(=O)C=1C=NNC=1 VFTZKSMAJVLWOV-UHFFFAOYSA-N 0.000 description 2
- SLDBCBDKAUNYHY-UHFFFAOYSA-N methyl 3-fluoro-5-(hydroxymethyl)benzoate Chemical compound COC(=O)C1=CC(F)=CC(CO)=C1 SLDBCBDKAUNYHY-UHFFFAOYSA-N 0.000 description 2
- VLFQXVIURJDHTO-UHFFFAOYSA-N methyl 3-fluoro-5-formylbenzoate Chemical compound COC(=O)C1=CC(F)=CC(C=O)=C1 VLFQXVIURJDHTO-UHFFFAOYSA-N 0.000 description 2
- BAJJMGRQZURDLB-UHFFFAOYSA-N methyl 4-formyl-1h-pyrazole-5-carboxylate Chemical compound COC(=O)C=1NN=CC=1C=O BAJJMGRQZURDLB-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- WXGBZJJAGLSBPR-UHFFFAOYSA-N (2-fluoropyridin-4-yl)boronic acid Chemical compound OB(O)C1=CC=NC(F)=C1 WXGBZJJAGLSBPR-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- JNOVZPGBPRDTHN-UHFFFAOYSA-N (4-bromopyridin-2-yl)hydrazine Chemical compound NNC1=CC(Br)=CC=N1 JNOVZPGBPRDTHN-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229930007886 (R)-camphor Natural products 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- AGRIQBHIKABLPJ-UHFFFAOYSA-N 1-Pyrrolidinecarboxaldehyde Chemical compound O=CN1CCCC1 AGRIQBHIKABLPJ-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- SURKZMFXICWLHU-UHFFFAOYSA-N 2-bromo-4-chloropyridine Chemical compound ClC1=CC=NC(Br)=C1 SURKZMFXICWLHU-UHFFFAOYSA-N 0.000 description 1
- DXJRTALWSLFSOY-UHFFFAOYSA-N 2-bromo-4-fluoro-5-methylpyridine Chemical compound CC1=CN=C(Br)C=C1F DXJRTALWSLFSOY-UHFFFAOYSA-N 0.000 description 1
- AIEATTRZKVGMBO-UHFFFAOYSA-N 2-bromo-4-fluoropyridine Chemical compound FC1=CC=NC(Br)=C1 AIEATTRZKVGMBO-UHFFFAOYSA-N 0.000 description 1
- ZIDIKYIZXMYHAW-UHFFFAOYSA-N 2-bromo-6-fluoropyridine Chemical compound FC1=CC=CC(Br)=N1 ZIDIKYIZXMYHAW-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- YNXYTOJEFCKHEM-UHFFFAOYSA-N 3-[2-[(3-chloro-5-fluorophenyl)methyl]-1-benzothiophen-7-yl]-n-(2-methoxyethyl)benzamide Chemical compound COCCNC(=O)C1=CC=CC(C=2C=3SC(CC=4C=C(Cl)C=C(F)C=4)=CC=3C=CC=2)=C1 YNXYTOJEFCKHEM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- WLJIPMNJIBKQON-UHFFFAOYSA-N 4-formyl-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C1=NNC=C1C=O WLJIPMNJIBKQON-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- REWXOSLNIMFERQ-UHFFFAOYSA-N BrC1=CC(=NC=C1)N1N=C(C(=C1)C(=O)OCC)C Chemical compound BrC1=CC(=NC=C1)N1N=C(C(=C1)C(=O)OCC)C REWXOSLNIMFERQ-UHFFFAOYSA-N 0.000 description 1
- MAMRQBXCYXTUAS-UHFFFAOYSA-N BrC1=NC=C(C(=C1)N1N=C(C(=C1)C(=O)OCC)C)C Chemical compound BrC1=NC=C(C(=C1)N1N=C(C(=C1)C(=O)OCC)C)C MAMRQBXCYXTUAS-UHFFFAOYSA-N 0.000 description 1
- 208000021465 Brief psychotic disease Diseases 0.000 description 1
- SEOXFZNHFLLSPM-UHFFFAOYSA-N C(C)OC(=O)C=1C(=NN(C=1)C1=NC=CC(=C1)B(O)O)C Chemical compound C(C)OC(=O)C=1C(=NN(C=1)C1=NC=CC(=C1)B(O)O)C SEOXFZNHFLLSPM-UHFFFAOYSA-N 0.000 description 1
- HPSFKOJCCRNRLW-UHFFFAOYSA-N C(N)(=O)C=1C(=NN(C=1)C1=NC(=CC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F)C(=O)OC Chemical compound C(N)(=O)C=1C(=NN(C=1)C1=NC(=CC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F)C(=O)OC HPSFKOJCCRNRLW-UHFFFAOYSA-N 0.000 description 1
- GOFXUKDPDADRQS-UHFFFAOYSA-N C1(N2C(=C(C(=O)O)C(C)=N2)CO)=CC(CC2=CC(F)=CC(C(F)(F)F)=C2)=NC=C1 Chemical compound C1(N2C(=C(C(=O)O)C(C)=N2)CO)=CC(CC2=CC(F)=CC(C(F)(F)F)=C2)=NC=C1 GOFXUKDPDADRQS-UHFFFAOYSA-N 0.000 description 1
- KKNUHLWQYUADTR-UHFFFAOYSA-N C1=C(N2N=C(C(CO)=C2)C(=O)O)N=C(CC2=CC(F)=CC(C(F)(F)F)=C2)C=C1 Chemical compound C1=C(N2N=C(C(CO)=C2)C(=O)O)N=C(CC2=CC(F)=CC(C(F)(F)F)=C2)C=C1 KKNUHLWQYUADTR-UHFFFAOYSA-N 0.000 description 1
- UZFLWFTWUZMLAN-UHFFFAOYSA-N C1=NC(=CC(CC2=CC(F)=CC(C(F)F)=C2)=C1)N1C(=C(C(=O)O)C(C)=N1)CO Chemical compound C1=NC(=CC(CC2=CC(F)=CC(C(F)F)=C2)=C1)N1C(=C(C(=O)O)C(C)=N1)CO UZFLWFTWUZMLAN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UWQWDJQQFZKSKW-UHFFFAOYSA-N ClC1=NN(C=C1C(=O)OCC)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F Chemical compound ClC1=NN(C=C1C(=O)OCC)C1=CC(=NC=C1)CC1=CC(=CC(=C1)C(F)(F)F)F UWQWDJQQFZKSKW-UHFFFAOYSA-N 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001480079 Corymbia calophylla Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 240000001414 Eucalyptus viminalis Species 0.000 description 1
- LZFHELPZLBWHOY-UHFFFAOYSA-N FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)O)C=C(C=1)F)F Chemical compound FC(C=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)O)C=C(C=1)F)F LZFHELPZLBWHOY-UHFFFAOYSA-N 0.000 description 1
- PNQSKSJOEAJSKR-UHFFFAOYSA-N FC=1C=C(C(=O)C2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(C(=O)C2=NC=CC(=C2)N2N=C(C(=C2)C(=O)N)C)C=C(C=1)C(F)(F)F PNQSKSJOEAJSKR-UHFFFAOYSA-N 0.000 description 1
- BQUVCHBHQSEALG-UHFFFAOYSA-N FC=1C=C(C(=O)C2=NC=CC(=C2)N2N=C(C(=C2)C(=O)OCC)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(C(=O)C2=NC=CC(=C2)N2N=C(C(=C2)C(=O)OCC)C)C=C(C=1)C(F)(F)F BQUVCHBHQSEALG-UHFFFAOYSA-N 0.000 description 1
- JBBWPCTTYSSJIR-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C)C(=O)O)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C)C(=O)O)C=C(C=1)C(F)(F)F JBBWPCTTYSSJIR-UHFFFAOYSA-N 0.000 description 1
- JPYCMSVTKQAEKH-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C=O)C(=O)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2)C=O)C(=O)OC)C=C(C=1)C(F)(F)F JPYCMSVTKQAEKH-UHFFFAOYSA-N 0.000 description 1
- RKTMRBQYIZQGLV-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2C)C(=O)OC)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2C)C(=O)OC)C)C=C(C=1)C(F)(F)F RKTMRBQYIZQGLV-UHFFFAOYSA-N 0.000 description 1
- CQEKUEGJMQIPSK-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2CO)C(=O)O)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C(=C2CO)C(=O)O)C)C=C(C=1)C(F)(F)F CQEKUEGJMQIPSK-UHFFFAOYSA-N 0.000 description 1
- DASIEWZVHDLMDP-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)O)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2)C(=O)O)C=C(C=1)C(F)(F)F DASIEWZVHDLMDP-UHFFFAOYSA-N 0.000 description 1
- NAJYTBIXDPHXCP-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C(=O)O)C(=O)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C(=O)O)C(=O)OC)C=C(C=1)C(F)(F)F NAJYTBIXDPHXCP-UHFFFAOYSA-N 0.000 description 1
- AACSSBXUUSLCMD-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C(=O)OC)C(=O)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C(=O)OC)C(=O)OC)C=C(C=1)C(F)(F)F AACSSBXUUSLCMD-UHFFFAOYSA-N 0.000 description 1
- XKIAZBFGHLZFSJ-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C(=O)OC)CO)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C(=O)OC)CO)C=C(C=1)C(F)(F)F XKIAZBFGHLZFSJ-UHFFFAOYSA-N 0.000 description 1
- FFYKOLLGTDTYTH-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C)C(=O)O)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2C)C(=O)O)C=C(C=1)C(F)(F)F FFYKOLLGTDTYTH-UHFFFAOYSA-N 0.000 description 1
- GQNMPBXTYUHVJX-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2CO)C(=O)O)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2CO)C(=O)O)C=C(C=1)C(F)(F)F GQNMPBXTYUHVJX-UHFFFAOYSA-N 0.000 description 1
- TZMROCIETYVCQP-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2CO)C(=O)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=C(C=C2CO)C(=O)OC)C=C(C=1)C(F)(F)F TZMROCIETYVCQP-UHFFFAOYSA-N 0.000 description 1
- SUTHNWNGKVXBKG-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2)C(=O)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2)C(=O)OC)C=C(C=1)C(F)(F)F SUTHNWNGKVXBKG-UHFFFAOYSA-N 0.000 description 1
- REKZFGGBOCNMAI-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2C)C(=O)O)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2C)C(=O)O)C=C(C=1)C(F)(F)F REKZFGGBOCNMAI-UHFFFAOYSA-N 0.000 description 1
- LWPNXONYYGAXPF-UHFFFAOYSA-N FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2C)C(=O)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC(=NC=C2)N2N=CC(=C2C)C(=O)OC)C=C(C=1)C(F)(F)F LWPNXONYYGAXPF-UHFFFAOYSA-N 0.000 description 1
- BFYJWIPQWWLCIL-UHFFFAOYSA-N FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)C=O)C(=O)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=CC=CC(=N2)N2N=C(C(=C2)C=O)C(=O)OC)C=C(C=1)C(F)(F)F BFYJWIPQWWLCIL-UHFFFAOYSA-N 0.000 description 1
- NLVWXTCHOSETHV-UHFFFAOYSA-N FC=1C=C(CC2=NC=C(C(=C2)N2N=C(C(=C2)C(=O)O)C)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=C(C(=C2)N2N=C(C(=C2)C(=O)O)C)C)C=C(C=1)C(F)(F)F NLVWXTCHOSETHV-UHFFFAOYSA-N 0.000 description 1
- VMLMRRAJKSQWBN-UHFFFAOYSA-N FC=1C=C(CC2=NC=C(C(=C2)N2N=C(C(=C2)C(=O)OCC)C)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=C(C(=C2)N2N=C(C(=C2)C(=O)OCC)C)C)C=C(C=1)C(F)(F)F VMLMRRAJKSQWBN-UHFFFAOYSA-N 0.000 description 1
- OLJYBETUKUAWHX-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)OC)C)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)OC)C)C=C(C=1)C(F)(F)F OLJYBETUKUAWHX-UHFFFAOYSA-N 0.000 description 1
- INFFTHPULKYWTP-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)OCC)OC)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C(=C2)C(=O)OCC)OC)C=C(C=1)C(F)(F)F INFFTHPULKYWTP-UHFFFAOYSA-N 0.000 description 1
- IBAKHYDBWFJHOG-UHFFFAOYSA-N FC=1C=C(CC2=NC=CC(=C2)N2N=C(C=C2)C(=O)O)C=C(C=1)C(F)(F)F Chemical compound FC=1C=C(CC2=NC=CC(=C2)N2N=C(C=C2)C(=O)O)C=C(C=1)C(F)(F)F IBAKHYDBWFJHOG-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- SOXPQVUBMIEVIR-UHFFFAOYSA-N OS(O)(=O)=O.F.F.F Chemical compound OS(O)(=O)=O.F.F.F SOXPQVUBMIEVIR-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000033390 Paroxysmal kinesigenic dyskinesia Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MIOPJNTWMNEORI-OMNKOJBGSA-N [(4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-OMNKOJBGSA-N 0.000 description 1
- VUXUOFWAYYQQGC-UHFFFAOYSA-N [B]C1=CC=NC(F)=C1 Chemical compound [B]C1=CC=NC(F)=C1 VUXUOFWAYYQQGC-UHFFFAOYSA-N 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 150000005524 benzylchlorides Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- SIPQVJNEQSWAOK-UHFFFAOYSA-N dimethyl 1h-pyrazole-3,5-dicarboxylate Chemical compound COC(=O)C=1C=C(C(=O)OC)NN=1 SIPQVJNEQSWAOK-UHFFFAOYSA-N 0.000 description 1
- XEOLLJWHFPBAMQ-UHFFFAOYSA-N dimethyl 5-fluorobenzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC(F)=CC(C(=O)OC)=C1 XEOLLJWHFPBAMQ-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000035548 disruptive behavior disease Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FNASCUBBFNCFQO-SOFGYWHQSA-N ethyl (2e)-2-(ethoxymethylidene)-3-oxobutanoate Chemical compound CCO\C=C(/C(C)=O)C(=O)OCC FNASCUBBFNCFQO-SOFGYWHQSA-N 0.000 description 1
- QIBGZMYYGTXSQD-UHFFFAOYSA-N ethyl 4-methyl-1h-pyrazole-5-carboxylate Chemical compound CCOC(=O)C1=NNC=C1C QIBGZMYYGTXSQD-UHFFFAOYSA-N 0.000 description 1
- WNRMFDPBDDKWFD-UHFFFAOYSA-N ethyl 5-chloro-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1Cl WNRMFDPBDDKWFD-UHFFFAOYSA-N 0.000 description 1
- VXHCBKUFAXDEDI-UHFFFAOYSA-N ethyl 5-methoxy-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CNN=C1OC VXHCBKUFAXDEDI-UHFFFAOYSA-N 0.000 description 1
- HHYVTIKYZUMDIL-UHFFFAOYSA-N ethyl 5-methyl-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1C HHYVTIKYZUMDIL-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 150000005754 fluoropyridines Chemical class 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000057295 human GPR52 Human genes 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HYULAOVKUFWMCB-UHFFFAOYSA-N methyl 3,5-dimethyl-1h-pyrazole-4-carboxylate Chemical compound COC(=O)C=1C(C)=NNC=1C HYULAOVKUFWMCB-UHFFFAOYSA-N 0.000 description 1
- QGBPKJFJAVDUNC-UHFFFAOYSA-N methyl 4-methoxy-3-oxobutanoate Chemical compound COCC(=O)CC(=O)OC QGBPKJFJAVDUNC-UHFFFAOYSA-N 0.000 description 1
- GFEZEVUIYRGWNU-UHFFFAOYSA-N methyl 5-methyl-1h-pyrazole-3-carboxylate Chemical compound COC(=O)C=1C=C(C)NN=1 GFEZEVUIYRGWNU-UHFFFAOYSA-N 0.000 description 1
- CRMIQSQQCPLMIJ-UHFFFAOYSA-N methyl 5-methyl-1h-pyrazole-4-carboxylate Chemical compound COC(=O)C=1C=NNC=1C CRMIQSQQCPLMIJ-UHFFFAOYSA-N 0.000 description 1
- UIAFUZFURUTFNX-UHFFFAOYSA-N methyl 5-methyl-2h-triazole-4-carboxylate Chemical compound COC(=O)C=1N=NNC=1C UIAFUZFURUTFNX-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000007106 neurocognition Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical class OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 208000025874 separation anxiety disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000003638 stannyl group Chemical group [H][Sn]([H])([H])* 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 201000006137 substance-induced psychosis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000006411 tonic activation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- NFNLCUMEICAHQA-UHFFFAOYSA-N tributyl-(4-fluoropyridin-2-yl)stannane Chemical compound FC1=CC(=NC=C1)[Sn](CCCC)(CCCC)CCCC NFNLCUMEICAHQA-UHFFFAOYSA-N 0.000 description 1
- REDSKZBUUUQMSK-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC.CCCC[Sn](CCCC)CCCC REDSKZBUUUQMSK-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Amplifiers (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
Abstract
Description
Xは、NまたはCR5であり、
Yは、NまたはCR6であり、
R1は、H;OHもしくは1~6個のフッ素原子で置換されていてもよいC1~6アルキル;OHもしくは1~6個のフッ素原子で置換されていてもよいC3~6シクロアルキルであり、ここで、C1~6アルキルもしくはC3~6シクロアルキル基が、OHで置換されていない場合、C1~6アルキルもしくはC3~6シクロアルキル基の1個の原子は、Nに直接結合していないO原子により交換されていてもよく、もしくはNに直接結合している炭素原子に結合していてもよく、または、R1は、R2と一緒になって、OHもしくは1~6個のフッ素原子で置換されていてもよい4、5、6、もしくは7員環を形成し、
R2は、H;またはOHもしくは1~6個のフッ素原子で置換されていてもよいC1~3アルキルであり、あるいはR2は、R1と一緒になって、OHもしくは1~6個のフッ素原子で置換されていてもよい4、5、6、もしくは7員環を形成し、
R4、R5、およびR6は、H;CN;ハロ;OHまたは1~6個のフッ素原子で置換されていてもよいC1~6アルキル;OHまたは1~6個のフッ素原子で置換されていてもよいC3~6シクロアルキル;および1~6個のフッ素原子で置換されていてもよいC1~6アルコキシから独立して選択され、ここで、C1~6アルキルまたはC3~6シクロアルキル基がOHで置換されていない場合、C1~6アルキルまたはC3~6シクロアルキル基の1個の原子は、Oにより交換されていてもよく、
R3は、式:
式中、各Aは、独立して、NまたはCR7であり、
Lは、CH2またはCHOHであり、
各Bは、独立して、N、CR8、CR9、またはCR10であり、
R7は、H;ハロ;CN;および1~6個のフッ素原子で置換されていてもよいC1~3アルキルから選択され、
R8、R9、およびR10は、H;CN;ハロ;1~6個のフッ素原子で置換されていてもよいC1~6アルキル;および1~6個のフッ素原子で置換されていてもよいC1~6アルコキシから独立して選択され、ここで、C1~6アルキル基の1個の原子は、O、N、S、およびこれらの酸化形態から選択されるヘテロ原子により交換されていてもよい。
Xは、NまたはCR5であり、
Yは、NまたはCR6であり、
R1は、H;OHもしくは1~6個のフッ素原子で置換されていてもよいC1~6アルキル;OHもしくは1~6個のフッ素原子で置換されていてもよいC3~6シクロアルキルであり、ここで、C1~6アルキルもしくはC3~6シクロアルキル基が、OHで置換されていない場合、C1~6アルキルもしくはC3~6シクロアルキル基の1個の原子は、Nに直接結合していないO原子により交換されていてもよく、もしくはNに直接結合している炭素原子に結合していてもよく、または、R1は、R2と一緒になって、OHもしくは1~6個のフッ素原子で置換されていてもよい4、5、6、もしくは7員環を形成し、
R2は、H;またはOHもしくは1~6個のフッ素原子で置換されていてもよいC1~3アルキルであり、あるいはR2は、R1と一緒になって、OHもしくは1~6個のフッ素原子で置換されていてもよい4、5、6、もしくは7員環を形成し、
R4、R5、およびR6は、H;CN;ハロ;OHまたは1~6個のフッ素原子で置換されていてもよいC1~6アルキル;OHまたは1~6個のフッ素原子で置換されていてもよいC3~6シクロアルキル;および1~6個のフッ素原子で置換されていてもよいC1~6アルコキシから独立して選択され、ここで、C1~6アルキルまたはC3~6シクロアルキル基がOHで置換されていない場合、C1~6アルキルまたはC3~6シクロアルキル基の1個の原子は、Oにより交換されていてもよく、
R3は、式:
式中、各Aは、独立して、NまたはCR7であり、
Lは、CH2またはCHOHであり、
各Bは、独立して、N、CR8、CR9、またはCR10であり、
R7は、H;ハロ;CN;および1~6個のフッ素原子で置換されていてもよいC1~3アルキルから選択され、
R8、R9、およびR10は、H;CN;ハロ;1~6個のフッ素原子で置換されていてもよいC1~6アルキル;および1~6個のフッ素原子で置換されていてもよいC1~6アルコキシから独立して選択され、ここで、C1~6アルキル基の1個の原子は、O、N、S、およびこれらの酸化形態から選択されるヘテロ原子により交換されていてもよい。
Xは、NまたはCR5であり、
Yは、NまたはCR6であり、
R1は、H;OHもしくは1~6個のフッ素原子で置換されていてもよいC1~6アルキル;OHもしくは1~6個のフッ素原子で置換されていてもよいC3~6シクロアルキルであり、ここで、C1~6アルキルもしくはC3~6シクロアルキル基の1個の原子は、Oにより交換されていてもよく、または、R1は、R2と一緒になって、OHもしくは1~6個のフッ素原子で置換されていてもよい4、5、6、もしくは7員環を形成し、
R2は、H;またはOHもしくは1~6個のフッ素原子で置換されていてもよいC1~3アルキルであり、あるいはR2は、R1と一緒になって、OHもしくは1~6個のフッ素原子で置換されていてもよい4、5、6、もしくは7員環を形成し、
R4、R5、およびR6は、H;CN;ハロ;OHまたは1~6個のフッ素原子で置換されていてもよいC1~6アルキル;およびOHまたは1~6個のフッ素原子で置換されていてもよいC1~6アルコキシから独立して選択され、ここで、C1~6アルキル基がOHで置換されていない場合、C1~6アルキル基のいずれか1個の原子は、Oにより交換されていてもよく、
R3は、式:
式中、各Aは、独立して、NまたはCR7であり、
Lは、CH2またはCHOHであり、
各Bは、独立して、N、CR8、CR9、またはCR10であり、
R7は、H;ハロ;CN;および1~6個のフッ素原子で置換されていてもよいC1~3アルキルから選択され、
R8、R9、およびR10は、H;CN;ハロ;1~6個のフッ素原子で置換されていてもよいC1~6アルキル;および1~6個のフッ素原子で置換されていてもよいC1~6アルコキシから独立して選択され、ここで、C1~6アルキル基の1個の原子は、O、N、S、およびこれらの酸化形態から選択されるヘテロ原子により交換されていてもよい。
式中、各Aは、独立して、NまたはCR7であり、
Lは、CH2またはCHOHであり、
各Bは、独立して、N、CR8、CR9、またはCR10であり、
R7、R8、R9、およびR10は、H;ハロ;CN;および1~6個のフッ素原子で置換されていてもよいC1~3アルキルから独立して選択される。
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-メチル-1H-ピラゾール-4-カルボキサミド、
2-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-2H-1,2,3-トリアゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3,5-ジメチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-メチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-4-メチル-1H-ピラゾール-3-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メトキシ-1H-ピラゾール-4-カルボキサミド、
2-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-5-メチル-2H-1,2,3-トリアゾール-4-カルボキサミド、
2-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-メチル-2H-1,2,3-トリアゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-メトキシ-1H-ピラゾール-4-カルボキサミド、
1-(6-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-4-メチル-1H-ピラゾール-3-カルボキサミド、
(1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メチル-1H-ピラゾール-4-イル)(ピロリジン-1-イル)メタノン、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N,3-ジメチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N,N,3-トリメチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メチル-N-(オキセタン-3-イル)-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N-(2-ヒドロキシエチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N-(2-メトキシエチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
3-クロロ-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
3-(ジフルオロメチル)-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-(トリフルオロメチル)-1H-ピラゾール-4-カルボキサミド、
3-エチル-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
3-シアノ-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
3-シクロプロピル-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N,5-ジメチル-1H-ピラゾール-3-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-メチル-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-メチル-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N,N-ジメチル-1H-ピラゾール-3-カルボキサミド、
(1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-1H-ピラゾール-3-イル)(ピロリジン-1-イル)メタノン、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-(オキセタン-3-イル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-(2-ヒドロキシエチル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-(2-メトキシエチル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-(ジフルオロメチル)-5-フルオロベンジル)ピリジン-2-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-(ジフルオロメチル)-5-フルオロベンジル)ピリジン-2-イル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-(2-ヒドロキシエチル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N-(2-ヒドロキシエチル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-(ヒドロキシメチル)-N,3-ジメチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-(ジフルオロメチル)-5-フルオロベンジル)ピリジン-2-イル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-{[3-(ジフルオロメチル)-5-フルオロフェニル]メチル}ピリジン-2-イル)-N,3-ジメチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-(ジフルオロメチル)-5-フルオロベンジル)ピリジン-2-イル)-N-メチル-1H-ピラゾール-3-カルボキサミド、
1-(6-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-(ヒドロキシメチル)-1H-ピラゾール-4-カルボキサミド、
1-(6-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-(ヒドロキシメチル)-N-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-4-(ヒドロキシメチル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-4-(ヒドロキシメチル)-N-メチル-1H-ピラゾール-3-カルボキサミド、
1-(6-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-4-(ヒドロキシメチル)-1H-ピラゾール-3-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)-5-メチルピリジン-4-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-(ヒドロキシメチル)-5-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-(ヒドロキシメチル)-1H-ピラゾール-3-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N-メチル-1H-ピラゾール-3-カルボキサミド、
2-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-メチル-2H-1,2,3-トリアゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N,4-ジメチル-1H-ピラゾール-3-カルボキサミド、
2-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N,5-ジメチル-2H-1,2,3-トリアゾール-4-カルボキサミド、
1-(2-((3-フルオロ-5-(トリフルオロメチル)フェニル)(ヒドロキシ)メチル)ピリジン-4-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
またはその塩
からなる群から選択されうる。
本出願では、特に指示のない限り、以下の定義が適用される。
活性化合物を単独で投与することが可能であるが、医薬組成物(例えば、製剤)として提示されることが好ましい。
式(1)の化合物は、当業者に公知の合成方法に従って調製することができる。本発明はまた、上記の式(1)に定義されている化合物の調製過程を提供する。中間体が市販されている場合は、表3のケミカル・アブストラクツ・サービス(chemical abstracts service)(CAS)参照番号によって同定され、市販されていない場合は、標準的変換を使用する中間体の合成が本明細書に詳述される。市販の試薬を、さらに精製することなく利用した。
室温(RT)は、およそ20~27℃を指す。1H NMRスペクトルは、特定されない限り、典型的には400MHzにより周囲温度で記録した。化学シフト値は、百万分率(ppm)、すなわち、(δ)値で表す。標準的略語、またはこれらの組合せを、NMRシグナルの多重度のために使用し、例えば、s=一重項、br=広帯、d=二重項、t=三重項、q=四重項、quin=五重項またはp=五重項(pentet)、h=六重項、dd=二重項の二重項、dt=三重項の二重項、m=多重項である。結合定数を、Hzで測定してJ値として列挙する。NMRおよび質量分析の結果は、バックグラウンドピークを説明するために修正した。クロマトグラフィーは、シリカまたはC18シリカを使用して実施され、かつ正圧(フラッシュクロマトグラフィー)条件下で実行されるカラムクロマトグラフィーを指す。
LCMS実験を、以下の条件下でエレクトロスプレー条件を使用して行った(溶媒:A1=H2O中0.1%TFA:MeCN(95:5);A2=H2O中5mMの酢酸アンモニウム;A3=2.5LのH2O+2.5mLのH2O中28%アンモニア水;A4=H2O中0.1%HCO2H:MeCN(95:5);A5=H2O中10mMのNH4HCO3;A6=H2O中0.2%の28%アンモニア水;A7=H2O中0.1%のTFA;A8=pH7.4の50mMの酢酸アンモニウム;A9=H2O中10mMの酢酸アンモニウム;B1=MeCN中0.1%のTFA;B2=MeCN;B3=2.5LのMeCN+135mLのH2O+2.5mLのH2O中28%アンモニア水)。LCMSデータを、マスイオン、エレクトロスプレーモード(正または負)、滞留時間(実験テキストおよび表2);マスイオン、エレクトロスプレーモード(正または負)、滞留時間、おおよその純度(approximate purity)(表3)のフォーマットで提示する。
GCMSデータを、マスイオン、エレクトロスプレーモード(正または負)、滞留時間のフォーマットで提示する。
方法1.データは、緩衝液を使用してUPLCカラムで4~6分間実行した後に、Waters QDAまたはWaters SQD機器から得た。
溶媒条件によるLCMS方法のセクションを参照されたい。
aq=水性
DAST=(ジエチルアミノ)硫酸トリフルオリド
dba=ジベンジリデンアセトン
DCM=ジクロロメタン
Dess-Martin=1,1,1-トリス(アセチルオキシ)-1,1-ジヒドロ-1,2-ベンゾヨードキソール-3-(1H)-オン
DIPEA=N,N-ジイソプロピルエチルアミン
DMF=N,N-ジメチルホルムアミド
DMF-DMA=N,N-ジメチルホルムアミドジメチルアセタール
DMSO=ジメチルスルホキシド
dppf=1,1’-フェロセンジイル-ビス(ジフェニルホスフィン)
ES=エレクトロスプレー
EtOAc=酢酸エチル
EtOH=エタノール
h=時間
HATU=N-[(ジメチルアミノ)-1H-1,2,3-トリアゾロ-[4,5-b]ピリジン-1-イルメチレン]-N-メチルメタンアミニウムヘキサフルオロホスフェートN-オキシド
IPA=i-プロピルアルコール
L=リットル
LC=液体クロマトグラフィー
LCMS=液体クロマトグラフィー質量分析
MeCN=アセトニトリル
MeOH=メタノール
min=分
MS=質量分析
NMP=1-メチル-2-ピロリジノン
MMR=核磁気共鳴
Pet-ether=石油エーテル
pin=ピナコラト
RT=室温
RuPhos=2-ジシクロヘキシルホスフィノ-2’,6’-ジイソプロポキシビフェニル
T3P=2,4,6-トリプロピル-1,3,5,2,4,6-トリオキサトリホスホリナン-2,4,6-三酸化物
TFA=トリフルオロ酢酸
THF=テトラヒドロフラン
接頭辞のn-、s-、i-、t-およびtert-は、通常の意味を有し、直鎖状、第二級、イソ、および第三級である。
置換フルオロピリジン中間体の調製
中間経路1 中間体1の2-フルオロ-4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジンの調製によって例示する
MS(方法1):m/z 388(ES+)
ステップ2.1-(ブロモメチル)-3-フルオロ-5-(トリフルオロメチル)ベンゼン(1.33g、5.18mmol)を、1,4-ジオキサン(30mL)中の4-フルオロ-2-(トリブチルスタンニル)ピリジン(14.3g、5.18mmol)の溶液に添加した。反応混合物をアルゴンで10分間脱ガスし、CuI(98mg、0.51mmol)、Pd(PPh3)4(299mg、0.26mmol)を添加した。反応混合物を120℃で16時間加熱した。反応を水(30mL)でクエンチし、水層をEtOAc(2×100mL)で抽出した。合わせた有機層をブラインで洗浄し、乾燥し(Na2SO4)、溶媒を真空下で除去した。残留物を、ヘキサン中5~10%のEtOAcで溶出する勾配フラッシュカラムクロマトグラフィーにより精製して、4-フルオロ-2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジンを明黄色の液体(400mg、2つのステップで6.4%)としてもたらした。
表2のデータ。
中間経路4 中間体3の4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)-2-ヒドラジンイルピリジンの調製によって例示する
LCMS(方法1):m/z 290.1(ES+)、2.65分。
中間経路6 中間体4の1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メチル-1H-ピラゾール-4-カルボン酸の調製によって例示する
LCMS(方法4):m/z 394.3(ES+)、2.38分。
LCMS(方法4):m/z 378.3(ES+)、2.36分。
LCMS(方法4):m/z 394.0(ES+)、2.32分。
LCMS(方法1):m/z 187.9(ES-)、0.41分。
LCMS(方法1):m/z 310.0(ES+)、2.64分。
LCMS(方法11):m/z 276.1(ES+)、1.75分。
LCMS(方法11):m/z 390.0(ES+)、2.93分。
LCMS(方法1):m/z 438.0(ES+)、2.80分。
LCMS(方法14):m/z 408.0(ES+)、2.11分。
LCMS(方法12):m/z 408.0(ES+)、2.77分。
LCMS(方法13):m/z 324.0(ES+)、2.22分。
LCMS(方法1):m/z 410.0(ES+)、1.38分。
LCMS(方法1):m/z 422.0(ES+)、2.73分。
LCMS(方法11):m/z 437.9(ES+)、2.86分。
LCMS(方法15):m/z 423.9(ES+)、1.78および1.81分。
異性体1:
LCMS(方法11):m/z 409.9(ES+)、2.74分。
中間経路15 中間体10のエチル2-メチル-4-オキソ-4,5-ジヒドロフラン-3-カルボキシレートの調製によって例示する
中間経路17 中間体12の1-(クロロメチル)-3-(ジフルオロメチル)-5-フルオロベンゼンの調製によって例示する
GCMS(方法1):m/z 184.0(ES+)、7.34分。
GCMS(方法1):m/z 182.0(ES+)、6.76分。
GCMS(方法2):m/z 204.0(ES+)、2.36分。
GCMS(方法2):m/z 176.0(ES+)、6.36分。
調製例の典型的手順 下記の手順1~15による調製例によって例示する
手順1:
実施例1 1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-1H-ピラゾール-4-カルボキサミド
実施例3 1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-メチル-1H-ピラゾール-4-カルボキサミド
LCMS(方法4):m/z 380.1(ES+)、2.38分。
LCMS(方法4):m/z 366.0(ES+)、1.71分。
実施例6 1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3,5-ジメチル-1H-ピラゾール-4-カルボキサミド
LCMS(方法4):m/z 408.4(ES+)、2.45分。
LCMS(方法4):m/z 394.3(ES+)、1.88分。
実施例7 1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-メチル-1H-ピラゾール-4-カルボキサミド
LCMS(方法4):m/z 394.0(ES+)、2.51分。
LCMS(方法4):m/z 380.3(ES+)、1.76分。
実施例11 1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メトキシ-1H-ピラゾール-4-カルボキサミド
LCMS(方法6):m/z 424.2(ES+)、2.45分。
実施例12 2-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-5-メチル-2H-1,2,3-トリアゾール-4-カルボキサミド
LCMS(方法6):m/z 395.1(ES+)、2.47分。
実施例14 1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-メトキシ-1H-ピラゾール-4-カルボキサミド
LCMS(方法6):m/z 424.1(ES+)、2.63分。
実施例16 (1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メチル-1H-ピラゾール-4-イル)(ピロリジン-1-イル)メタノン
実施例20 1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N-(2-ヒドロキシエチル)-3-メチル-1H-ピラゾール-4-カルボキサミド
実施例22 3-クロロ-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド
LCMS(方法8):m/z 428.2(ES+)、1.85分。
実施例39 1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド
実施例40 1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-(2-ヒドロキシエチル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド
実施例47 1-(6-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-(ヒドロキシメチル)-1H-ピラゾール-4-カルボキサミド
LCMS(方法1):m/z 423.0(ES+)、2.26分。
実施例53 1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-(ヒドロキシメチル)-5-メチル-1H-ピラゾール-4-カルボキサミド、実施例39 1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド
LCMS(方法1):m/z 438.0(ES+)、2.64分。
LCMS(方法11):m/z 409.9(ES+)、2.36および2.40分。
実施例59 1-(2-((3-フルオロ-5-(トリフルオロメチル)フェニル)(ヒドロキシ)メチル)ピリジン-4-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド
生成物2:
LCMS(方法8):m/z 422.2(ES+)、1.92分。
GPR52アゴニストの機能性cAMPアッセイ
HEKf懸濁細胞を、哺乳類遺伝子発現用に設計された修飾バキュロウイルスである0.1%v/vのヒトGPR52発現BacMamウイルスで24時間感染させた。BacMam感染の後、細胞を遠心分離(335g、5分間)してペレット化し、細胞凍結培地(Sigma)に再懸濁し、必要になるまで-150℃で凍結させた。実験の当日、DMSOで調製した25nLのGPR52化合物希釈液を、LabCyte ECHOアコースティックディスペンサーによりプロキシプレート(proxiplate)(PerkinElmer)にスタンプした。凍結細胞を解凍し、0.5mMの3-イソ-ブチル-1-メチルキサンチン(IBMX,Sigma)を含有するアッセイ刺激緩衝液(Cisbio)に再懸濁して、ウエル1つ当たり2000個の細胞密度を達成した。10μlの細胞を、遠心分離(335g、1分間)する前に、Multidrop Combi Reagent Dispenser(ThermoFisher)を使用してアッセイプレートに添加した。製造会社の取扱説明書に従って調製したcAMP検出試薬(HiRange cAMPキット,Cisbio)を添加する前に、細胞を化合物と共に37℃で30分間インキュベートした。プレートを、標準HTRF設定を使用するPHERAstar FSプレートリーダー(BMG Labtech)で読み取る前に、室温で1時間振とうした。HTRF比は、アクセプター発光(665nm)をドナー発光(620nm)で割り、10,000を掛けることによって得た。データを、DMSO(0%)および最大3-(2-(3-クロロ-5-フルオロベンジル)ベンゾ[b]チオフェン-7-イル)-N-(2-メトキシエチル)ベンズアミド(J.Med.Chem.,2014,57,5226の化合物7m)の応答(100%)に対して正規化し、4パラメーターロジスティックフィット(4-parameter logistical fit)に適合させて、アゴニストのpEC50Sおよび最大応答を生成し、下記の表4に提示する。
実施例39の薬物動態プロファイルを、静脈内(IV)および経口(per os、PO)送達経路を介して雄Sprague-Dawleyラットで査定した。本発明の実施例39の薬物動態データ(平均値±標準偏差)を表5に詳述する。
血漿および脳曝露を、IV投与後の実施例39の脳浸透性を査定するために評価した。非結合脳/血漿比(unbound brain-to-plasma ratio)(Kp,uu)を、ラットの血漿および脳ホモジネートにおける結合を実験的に測定した後に計算し、表5に詳述した。
結合画分=(合計血漿または脳比)-(合計緩衝液比)/合計血漿または脳比
非結合画分(Fu脳または血漿)=1-結合画分
脳結合アッセイにおける希釈の修正:
未希釈Fu脳=(1/希釈係数)/((1/希釈Fu))-1)+(1/希釈係数)
式中、希釈係数=4である。
Claims (25)
- 式(1):
Xは、NまたはCR5であり、
Yは、NまたはCR6であり、
R1は、H;OHもしくは1~6個のフッ素原子で置換されていてもよいC1~6アルキル;OHもしくは1~6個のフッ素原子で置換されていてもよいC3~6シクロアルキルであり、ここで、C1~6アルキルもしくはC3~6シクロアルキル基が、OHで置換されていない場合、C1~6アルキルもしくはC3~6シクロアルキル基の1個の原子は、Nに直接結合していないO原子により交換されていてもよく、もしくはNに直接結合している炭素原子に結合していてもよく、または、R1は、R2と一緒になって、OHもしくは1~6個のフッ素原子で置換されていてもよい4、5、6、もしくは7員環を形成し、
R2は、H;またはOHもしくは1~6個のフッ素原子で置換されていてもよいC1~3アルキルであり、あるいはR2は、R1と一緒になって、OHもしくは1~6個のフッ素原子で置換されていてもよい4、5、6、もしくは7員環を形成し、
R4、R5、およびR6は、H;CN;ハロ;OHまたは1~6個のフッ素原子で置換されていてもよいC1~6アルキル;OHまたは1~6個のフッ素原子で置換されていてもよいC3~6シクロアルキル;および1~6個のフッ素原子で置換されていてもよいC1~6アルコキシから独立して選択され、ここで、C1~6アルキルまたはC3~6シクロアルキル基がOHで置換されていない場合、C1~6アルキルまたはC3~6シクロアルキル基の1個の原子は、Oにより交換されていてもよく、
R3は、式:
各Aは、独立して、NまたはCR7であり、
Lは、CH2またはCHOHであり、
各Bは、独立して、N、CR8、CR9、またはCR10であり、
R7は、H;ハロ;CN;および1~6個のフッ素原子で置換されていてもよいC1~3アルキルから選択され、
R8、R9、およびR10は、H;CN;ハロ;1~6個のフッ素原子で置換されていてもよいC1~6アルキル;および1~6個のフッ素原子で置換されていてもよいC1~6アルコキシから独立して選択され、ここで、C1~6アルキル基の1個の原子は、O、N、S、およびこれらの酸化形態から選択されるヘテロ原子により交換されていてもよい]。 - R1が、H、メチル、オキセタニル、CH2CH2OH、およびCH2CH2OCH3から選択され、またはR1が、R2と一緒になって、5員環を形成する、請求項1に記載の化合物。
- R2が、Hもしくはメチルであり、またはR1と一緒になって、5員環を形成する、請求項1または2に記載の化合物。
- Xが、N、CH、CCH3、またはCCH2OHである、請求項1から4のいずれか一項に記載の化合物。
- Yが、N、CH、またはCCH3である、請求項1から5のいずれか一項に記載の化合物。
- R4が、H、メチル、メトキシ、Cl、CHF2、CF3、エチル、CN、シクロプロピル、CH2OH、およびCH2OCH3から選択される、請求項1から6のいずれか一項に記載の化合物。
- R5およびR6が、H、メチル、およびCH2OHから独立して選択される、請求項1から4のいずれか一項に記載の化合物。
- Lが、CH2である、請求項1から11のいずれか一項に記載の化合物。
- R8、R9、およびR10が、H、F、CHF2、およびCF3から独立して選択される、請求項13から15のいずれか一項に記載の化合物。
- 1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-メチル-1H-ピラゾール-4-カルボキサミド、
2-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-2H-1,2,3-トリアゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3,5-ジメチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-メチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-4-メチル-1H-ピラゾール-3-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メトキシ-1H-ピラゾール-4-カルボキサミド、
2-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-5-メチル-2H-1,2,3-トリアゾール-4-カルボキサミド、
2-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-メチル-2H-1,2,3-トリアゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-メトキシ-1H-ピラゾール-4-カルボキサミド、
1-(6-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-4-メチル-1H-ピラゾール-3-カルボキサミド、
(1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メチル-1H-ピラゾール-4-イル)(ピロリジン-1-イル)メタノン、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N,3-ジメチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N,N,3-トリメチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-メチル-N-(オキセタン-3-イル)-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N-(2-ヒドロキシエチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N-(2-メトキシエチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
3-クロロ-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
3-(ジフルオロメチル)-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-3-(トリフルオロメチル)-1H-ピラゾール-4-カルボキサミド、
3-エチル-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
3-シアノ-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
3-シクロプロピル-1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N,5-ジメチル-1H-ピラゾール-3-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-メチル-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-メチル-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N,N-ジメチル-1H-ピラゾール-3-カルボキサミド、
(1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-1H-ピラゾール-3-イル)(ピロリジン-1-イル)メタノン、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-(オキセタン-3-イル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-(2-ヒドロキシエチル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-(2-メトキシエチル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-(ジフルオロメチル)-5-フルオロベンジル)ピリジン-2-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-(ジフルオロメチル)-5-フルオロベンジル)ピリジン-2-イル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-(2-ヒドロキシエチル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N-(2-ヒドロキシエチル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-(ヒドロキシメチル)-N,3-ジメチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-(ジフルオロメチル)-5-フルオロベンジル)ピリジン-2-イル)-5-(ヒドロキシメチル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-{[3-(ジフルオロメチル)-5-フルオロフェニル]メチル}ピリジン-2-イル)-N,3-ジメチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-(ジフルオロメチル)-5-フルオロベンジル)ピリジン-2-イル)-N-メチル-1H-ピラゾール-3-カルボキサミド、
1-(6-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-(ヒドロキシメチル)-1H-ピラゾール-4-カルボキサミド、
1-(6-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-(ヒドロキシメチル)-N-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-4-(ヒドロキシメチル)-1H-ピラゾール-3-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-4-(ヒドロキシメチル)-N-メチル-1H-ピラゾール-3-カルボキサミド、
1-(6-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-4-(ヒドロキシメチル)-1H-ピラゾール-3-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)-5-メチルピリジン-4-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-3-(ヒドロキシメチル)-5-メチル-1H-ピラゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-5-(ヒドロキシメチル)-1H-ピラゾール-3-カルボキサミド、
1-(2-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-4-イル)-N-メチル-1H-ピラゾール-3-カルボキサミド、
2-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N-メチル-2H-1,2,3-トリアゾール-4-カルボキサミド、
1-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N,4-ジメチル-1H-ピラゾール-3-カルボキサミド、
2-(4-(3-フルオロ-5-(トリフルオロメチル)ベンジル)ピリジン-2-イル)-N,5-ジメチル-2H-1,2,3-トリアゾール-4-カルボキサミド、
1-(2-((3-フルオロ-5-(トリフルオロメチル)フェニル)(ヒドロキシ)メチル)ピリジン-4-イル)-3-メチル-1H-ピラゾール-4-カルボキサミド、
またはその塩
からなる群から選択される、請求項1に記載の化合物。 - GPR52受容体モジュレーター活性を有する、請求項1から18のいずれか一項に記載の化合物。
- GPR52受容体アゴニストとしての使用のための、請求項1から18のいずれか一項に記載の化合物。
- 請求項1から20のいずれか一項に定義されている化合物と、薬学的に許容される賦形剤とを含む医薬組成物。
- 医薬における使用のための、請求項1から20のいずれか一項に記載の化合物、または請求項21に記載の医薬組成物。
- 精神障害;神経精神障害;神経変性障害;精神障害;認知障害;神経認知障害;錐体外路障害;運動障害;運動性障害;運動過剰障害;緊張病;気分障害;抑うつ障害;不安障害;強迫性障害(OCD);自閉スペクトラム症;抑うつ障害;視床下部障害;下垂体障害;プロラクチン関連障害;外傷またはストレス要因関連障害;破壊的な衝動制御または行為障害;睡眠覚醒障害;物質関連障害;嗜癖障害;行動障害;前頭葉機能低下;隆起漏斗、中脳辺縁系、中脳皮質または黒質線条体経路における異常;線条体における活性の減少;皮質機能不全;神経認知機能不全;またはこれらに関連する状態もしくは症状の処置における使用のための、請求項1から20のいずれか一項に記載の化合物、または請求項21に記載の医薬組成物。
- 障害または症状が、統合失調症、抑うつ、注意欠陥多動障害(ADHD)、全般性不安障害、強迫性障害(OCD)、パニック障害、双極性障害、嗜癖/衝動制御障害、自閉スペクトラム症、精神病、快感消失、激越、アルツハイマー病、パーキンソン病、ハンチントン病、血管性認知症、レビー小体病、前頭側頭型認知症、トゥレット症候群、高プロラクチン血症、下垂体腺腫、プロラクチノーマ、頭蓋咽頭腫、クッシング病、尿崩症、非機能性腫瘍、肥満症、外傷後ストレス障害(PTSD)、アカシジアおよび関連する運動、アテトーシス、運動失調、バリズム、片側バリズム、舞踏病、舞踏病アテトーゼ、ジスキネジア、遅発性ジスキネジア、神経遮断薬誘発性ジスキネジア、ミオクローヌス、鏡像運動障害、発作性運動誘発性ジスキネジア、下肢静止不能症候群、攣縮、常同運動症、ステロタイピイ、チック症、振戦、ウィルソン病、統合失調型パーソナリティ障害、妄想性障害、短期精神病性障害、統合失調症様障害、統合失調感情障害、物質または服薬誘発性精神障害、妄想、幻覚、支離滅裂な思考、ひどく混乱した、または異常な運動行動、緊張病、大うつ病性障害、双極I型障害、双極II型障害、気分循環性障害、物質または服薬誘発性双極性および関連障害、別の医学的状態が原因の双極性および関連障害、分離不安障害、場面緘黙、限局性恐怖症、社交不安症、パニック障害、広場恐怖症、全般不安症、物質または服薬誘発性不安障害、別の医学的状態が原因の不安障害、せん妄、重度神経認知障害、軽度神経認知障害、健忘症、認知症、発達性協調運動症、常同運動症、卒中後の影響、歯状核赤核淡蒼球ルイ体萎縮症、感情表現の減少、意欲消失、アロギー、および非社交性から選択される、請求項23に記載の使用のための化合物または医薬組成物。
- 障害または症状が、統合失調症、抑うつ、注意欠陥多動障害(ADHD)、全般性不安障害、強迫性障害(OCD)、パニック障害、双極性障害、嗜癖/衝動制御障害、自閉スペクトラム症、精神病、神経認知障害、せん妄、快感消失、激越、アルツハイマー病、パーキンソン病、ハンチントン病、血管性認知症、レビー小体病、前頭側頭型認知症、トゥレット症候群、高プロラクチン血症、肥満症、および外傷後ストレス障害(PTSD)から選択される、請求項23に記載の使用のための化合物または医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2003668.7A GB202003668D0 (en) | 2020-03-13 | 2020-03-13 | GPR52 Modulator compounds |
GB2003668.7 | 2020-03-13 | ||
PCT/GB2021/050638 WO2021181122A1 (en) | 2020-03-13 | 2021-03-15 | Gpr52 modulator compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2023519666A true JP2023519666A (ja) | 2023-05-12 |
JPWO2021181122A5 JPWO2021181122A5 (ja) | 2024-03-27 |
JP7492597B2 JP7492597B2 (ja) | 2024-05-29 |
Family
ID=70453676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022555137A Active JP7492597B2 (ja) | 2020-03-13 | 2021-03-15 | Gpr52モジュレーター化合物 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4117784A1 (ja) |
JP (1) | JP7492597B2 (ja) |
KR (1) | KR20220152296A (ja) |
CN (1) | CN115515681A (ja) |
AU (1) | AU2021235257A1 (ja) |
BR (1) | BR112022018287A2 (ja) |
CA (1) | CA3175429A1 (ja) |
GB (1) | GB202003668D0 (ja) |
IL (1) | IL296413A (ja) |
MX (1) | MX2022011333A (ja) |
WO (1) | WO2021181122A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022232017A1 (en) * | 2021-04-26 | 2022-11-03 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
GB202113186D0 (en) | 2021-09-15 | 2021-10-27 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
WO2024091538A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
WO2024091542A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
WO2024091541A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037797A1 (en) * | 2003-10-21 | 2005-04-28 | Pharmacia Corporation | Substituted pyrazole urea compounds for the treatment of inflammation |
US20110009421A1 (en) | 2008-02-27 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Compound having 6-membered aromatic ring |
WO2011078360A1 (ja) | 2009-12-24 | 2011-06-30 | 武田薬品工業株式会社 | アミド化合物 |
JPWO2011093352A1 (ja) | 2010-01-27 | 2013-06-06 | 武田薬品工業株式会社 | チアゾール誘導体 |
CA2984153A1 (en) * | 2015-04-29 | 2016-11-03 | Arena Pharmaceuticals, Inc. | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto |
WO2019053090A1 (en) | 2017-09-13 | 2019-03-21 | Novartis Ag | DIPHENYL DERIVATIVES AND USES THEREOF |
-
2020
- 2020-03-13 GB GBGB2003668.7A patent/GB202003668D0/en not_active Ceased
-
2021
- 2021-03-15 BR BR112022018287A patent/BR112022018287A2/pt unknown
- 2021-03-15 KR KR1020227035100A patent/KR20220152296A/ko unknown
- 2021-03-15 CN CN202180033813.9A patent/CN115515681A/zh active Pending
- 2021-03-15 JP JP2022555137A patent/JP7492597B2/ja active Active
- 2021-03-15 WO PCT/GB2021/050638 patent/WO2021181122A1/en active Application Filing
- 2021-03-15 CA CA3175429A patent/CA3175429A1/en active Pending
- 2021-03-15 EP EP21713103.6A patent/EP4117784A1/en active Pending
- 2021-03-15 MX MX2022011333A patent/MX2022011333A/es unknown
- 2021-03-15 IL IL296413A patent/IL296413A/en unknown
- 2021-03-15 AU AU2021235257A patent/AU2021235257A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL296413A (en) | 2022-11-01 |
BR112022018287A2 (pt) | 2022-11-22 |
CA3175429A1 (en) | 2021-09-16 |
EP4117784A1 (en) | 2023-01-18 |
CN115515681A (zh) | 2022-12-23 |
WO2021181122A1 (en) | 2021-09-16 |
GB202003668D0 (en) | 2020-04-29 |
KR20220152296A (ko) | 2022-11-15 |
MX2022011333A (es) | 2022-12-08 |
AU2021235257A1 (en) | 2022-10-06 |
JP7492597B2 (ja) | 2024-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7492597B2 (ja) | Gpr52モジュレーター化合物 | |
US11021446B2 (en) | Compositions and methods for modulating farnesoid X receptors | |
US11976062B2 (en) | Benzisoxazole compound | |
CA2945077A1 (en) | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors | |
AU2010229142A1 (en) | P2X3, receptor antagonists for treatment of pain | |
AU2010229144A1 (en) | P2X3, receptor antagonists for treatment of pain | |
JP2012507512A (ja) | アミロイドβのモジュレーター | |
AU2019214048B2 (en) | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes | |
JP2017519025A (ja) | チオフェン−2−イル−ピリジン−2−イル−1h−ピラゾール−4−カルボン酸誘導体、および可溶性グアニル酸シクラーゼ活性化剤としてのその使用 | |
JP2017095366A (ja) | 新規ビアリールアミド誘導体 | |
JP2008533193A (ja) | オキシトシン拮抗薬としての置換トリアゾール誘導体 | |
JPWO2012036278A1 (ja) | グリシントランスポーター阻害物質 | |
JP2023501984A (ja) | Gpr52モジュレーター化合物 | |
CN111526877A (zh) | 用于ire1抑制的化合物和组合物 | |
WO2021079962A1 (ja) | 難聴の予防および/または治療用医薬組成物 | |
JP2019511466A (ja) | オレキシン受容体調節因子としてのハロ置換ピペリジン | |
WO2017073743A1 (ja) | 三環性化合物 | |
WO2019054430A1 (ja) | 芳香族複素環を有するアミド化合物 | |
KR20130143141A (ko) | 피라졸리딘-3-온 유도체 | |
TW202220971A (zh) | 二氟甲基-吡啶-2-基三唑 | |
US20040058970A1 (en) | Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands | |
JP2023539336A (ja) | Gpr52モジュレーター化合物 | |
CA3232606A1 (en) | Gpr52 modulator compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240315 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240315 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20240315 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240418 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240517 |